Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Orasure Technologies ( (OSUR) ) has provided an update.
On February 28, 2026, OraSure Technologies, Inc. announced that board member David J. Shulkin, M.D. had notified the company of his decision to resign as director and as a member of the Board’s Compensation Committee, effective March 2, 2026. The company stated that Shulkin’s departure was not the result of any dispute with management or the board, and the directors expressed appreciation for his years of service, signaling an orderly governance transition without apparent internal conflict.
The most recent analyst rating on (OSUR) stock is a Hold with a $3.00 price target. To see the full list of analyst forecasts on Orasure Technologies stock, see the OSUR Stock Forecast page.
Spark’s Take on OSUR Stock
According to Spark, TipRanks’ AI Analyst, OSUR is a Neutral.
The score is held back primarily by deteriorated financial performance (losses, sharp revenue contraction, and recent cash burn). The latest earnings call provides partial support via stabilization signals (improving gross margin outlook, strong cash/no debt, and product-catalyst pipeline), while technicals are neutral-to-slightly positive and valuation remains challenged due to negative earnings.
To see Spark’s full report on OSUR stock, click here.
More about Orasure Technologies
OraSure Technologies, Inc. operates in the medical diagnostics industry, developing and selling diagnostic products and specimen collection devices. The company focuses on technologies that enable easy and accurate testing in clinical and at-home settings for various health conditions and infectious diseases.
Average Trading Volume: 570,751
Technical Sentiment Signal: Sell
Current Market Cap: $213.8M
For detailed information about OSUR stock, go to TipRanks’ Stock Analysis page.